SEC Form 4 · accession 0001193125-26-273321
BELITE BIO, INC · BLTE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Hendrik Peter Scholl
Officer — Chief Medical Officer
Period of report
Jun 16, 2026
Accepted (ET)
Jun 17, 2026 · 6:03 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001889109
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| American depositary shareF1,F2 | Jun 16, 2026 | S | 2,054 | $137.6053 | D | 32,946 | I | By Bioptima Ltd. |
| American depositary shareF1,F3 | Jun 16, 2026 | S | 784 | $138.1767 | D | 32,162 | I | By Bioptima Ltd. |
| American depositary shareF1,F4 | Jun 16, 2026 | S | 3,140 | $139.5734 | D | 29,022 | I | By Bioptima Ltd. |
| American depositary shareF1,F5 | Jun 16, 2026 | S | 540 | $140.5828 | D | 28,482 | I | By Bioptima Ltd. |
| American depositary shareF1 | Jun 16, 2026 | S | 100 | $141.83 | D | 28,382 | I | By Bioptima Ltd. |
| American depositary shareF1,F6 | Jun 16, 2026 | S | 450 | $142.1958 | D | 27,932 | I | By Bioptima Ltd. |
| American depositary shareF1,F7 | Jun 16, 2026 | S | 1,897 | $143.55 | D | 26,035 | I | By Bioptima Ltd. |
| American depositary shareF1,F8 | Jun 16, 2026 | S | 1,035 | $145.0212 | D | 25,000 | I | By Bioptima Ltd. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.
- F2Represents the weighted average price of shares sold at prices that ranged from $137.19 to $137.9. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
- F3Represents the weighted average price of shares sold at prices that ranged from $138 to $138.74. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
- F4Represents the weighted average price of shares sold at prices that ranged from $139.01 to $139.9575. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
- F5Represents the weighted average price of shares sold at prices that ranged from $140.325 to $140.825. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
- F6Represents the weighted average price of shares sold at prices that ranged from $142.14 to $142.24. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
- F7Represents the weighted average price of shares sold at prices that ranged from $143.035 to $143.915. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
- F8Represents the weighted average price of shares sold at prices that ranged from $145.02 to $145.6. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.